All In Biotech

NDA 204629 · Boehringer Ingelheim

Jardiance

Empagliflozin · Oral · Sodium-Glucose Cotransporter 2 Inhibitor

Novel

Last checked: Nov 20, 2026Latest source record: Oct 24, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2014

Aug 1, 2014

Approved uses

10

Original approval plus efficacy supplements

Registered trials

544

123 Phase 3, 99 recruiting

FAERS reports

69,480

42,385 serious, 3,511 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Nov 10, 2026.

JARDIANCE is indicated: to reduce the risk of cardiovascular death and hospitalization for heart failure in adults with heart failure. to reduce the risk of sustained decline in eGFR, end-stage kidney disease, cardiovascular death, and hospitalization in adults with chronic kidney disease at risk of progression. to reduce the risk of cardiovascular death in adults with type 2 diabetes mellitus and established cardiovascular disease. as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus. JARDIANCE is a sodium-glucose co-transporter 2 (SGLT2) inhibitor indicated: To reduce the risk of cardiovascular death and hospitalization for heart failure in adults with heart failure. ( 1 ) To reduce the risk of sustained decline in eGFR, end-stage kidney disease, cardiovascular death, and hospitalization in adults with chronic kidney disease at risk of progression. ( 1 ) To reduce the risk of cardiovascular death in adults with type 2 diabetes mellitus and established cardiovascular disease. ( 1 ) As an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus. ( 1 ) Limitations of Use: Not recommended for use to improve glycemic control in patients with type 1 diabetes mellitus. It may increase the risk of diabetic ketoacidosis in these patients. ( 1 ) Not recommended for use to improve glycemic control in patients with type 2 diabetes mellitus with an eGFR less than 30 mL/min/1.73 m 2 . ( 1 ) Not recommended for the treatment of chronic kidney disease in patients with polycystic kidney disease or patients requiring or with a recent history of intravenous immunosuppressive therapy or greater than 45 mg...

Mechanism: Empagliflozin is an inhibitor of SGLT2, the predominant transporter responsible for reabsorption of glucose from the glomerular filtrate back into the circulation. By inhibiting SGLT2, empagliflozin reduces renal reabsorption of filtered glucose and lowers the renal threshold for glucose, and thereby increases urinary glucose excretion. Empagliflozin also reduces sodium reabsorption and increases the delivery of sodium to the distal tubule. This may influence several physiological functions including, but not restricted to, increasing tubuloglomerular feedback and reducing intraglomerular...

Therapeutic areas: Cardiovascular and metabolic

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

2 products under this application
  • JARDIANCE · EMPAGLIFLOZIN 25MG · TABLET, ORAL · Prescription · TE AB
  • JARDIANCE · EMPAGLIFLOZIN 10MG · TABLET, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Empagliflozin" as an intervention, any sponsor and status, largest first.

All 544 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • diabetic ketoacidosis3,903
  • nausea3,728
  • diarrhoea3,406
  • blood glucose increased3,255
  • fatigue3,031
  • weight decreased3,000
  • off label use2,916
  • vomiting2,802
  • dizziness2,775
  • dyspnoea2,526
  • drug ineffective2,501
  • fungal infection2,167

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20137
2014163
2015759
20161,685
20172,444
20183,749
20195,480
20205,281
20216,152
20227,545
20239,191
20249,882
20259,631
20267,511

Recalls

2 FDA enforcement reports for this application.

  • Jan 26, 2022 · Class II · Terminated

    CGMP Deviations: Products were exposed to temperatures outside of the products labeled storage conditions.

  • Mar 9, 2023 · Class II · Terminated

    Labeling: Label Mix-up

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Jardiance (Empagliflozin)

2024 spending

$11.4B

Beneficiaries

2,543,331

11,368,280 claims

Per beneficiary

$4,496

$18.94 per unit

View as table
YearSpending
2020$2,376,166,293
2021$3,735,773,560
2022$5,851,720,782
2023$8,839,935,063
2024$11,435,997,421

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 813 on PubMed

Sponsor: Boehringer Ingelheim

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.